Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Race is Real:
In both cases – Yang and DNAPrint – “blind” studies of individuals correctly identify majority race with ~ 100% accuracy, as well as identify, in many cases, significant admixture consistent with known population histories and with individual phenotypes. The point being, in the last analysis, is that while a more perfect analysis would be able to detect “true ancestry” and complete “population diversity” (including Australian aboriginals, Papuans, etc.), the more limited set of AIMs and parental populations are currently sufficient to identify major racial and sub-racial populations, and admixture of these, by observing the patterns of genetic components characteristic of each group.
In any case, in summary:-
Race is real. And South Asians are a different race than Europeans. And the results of the Yang paper are generally consistent with the broad outlines of the racial and sub-racial DNAPrint data.
Ann
The Yang Paper & Reality of Race mentions DNAP:
http://majorityrights.com/index.php/weblog/comments/the_yang_paper_and_the_reality_of_race/
Ann
Progress on EPO:
Progress on EPO Dimmer:
"DNAPrint Genomics progresses anemia drug development"
Published: 15 Mar 2006
DNAPrint Genomics progresses anemia drug development
DNAPrint Genomics' development of commercial grade PT-401, a more powerful form of the anemia drug erythropoietin, is said to be proceeding on schedule with the manufacturing of PT-401 in mammalian cells being shown to be very efficient.
According to the company, erythropoietin (EPO) has a worldwide market exceeding $11 billion and is growing at an average annual rate of 18% for the past five years.
"Based on these results, research is on schedule for our first pharmaceutical product," stated Dr Hector Gomez, chairman and chief medical officer of DNAPrint Genomics. "Tests of our Super EPO dimer in animal models of anemia showed that it was several times more effective and longer acting than the currently available erythropoietin."
In vitro testing in cell cultures revealed significant positive biological activity shown by marked growth stimulation of target mammalian blood cells, either attached to solid surfaces or growing in suspension, according to Dr Gomez.
In addition, in vivo testing in mice demonstrated that even with a single injection, robust stimulation of red blood cell production was produced as assessed by an increase in the number and volume of blood cells. Further analytical testing showed that the dimer exhibits unique biochemical properties that distinguish it from currently marketed red blood cell growth stimulating drugs."
Ann
Ancestrty by DNA from DNAP website:
http://www.ancestrybydna.com/welcome/home/
Ann
Paulness:
"2 million shares that is a one big buy"
My chart showed that buy was cancelled.
Hope it proves out wrong...
Take care,
Ann
Impressve 1st Newsletter To Investors from DNAP:
"We invested heavily in the infrastructure and expertise needed to perform research of the highest caliber. Having built our foundation, we are now actively engaged in the development of our pipeline of genomics-based patient classification products. Most of our future expenses will be directly related to operating this pipeline.
We have constructed a library of SNP maps, showing where, in genes, individual human beings differ from one another. Our maps are by far the best in the world. Due mainly to our proprietary (and patent pending) protocols, our SNP maps are deeper and more detailed than those held publicly (NCBI) or privately (such as at Celera, Affymetrix, Incyte, Human Genome Sciences and even Gennaissance). Furthermore, our maps cover the entire length of the gene in the genome. The maps being constructed by others are focused at the ends. This is a crucial point because the depth and breadth of the maps are important! You can think of them as “treasure maps” - the more detailed and accurate the map, the better your chance of finding the treasure. As an investor in DNAPrint genomics, you should feel proud that you own a piece of the most comprehensive and valuable pharmaco-relevant SNP library on the planet.
We continue to write code for the high-throughput and automated mining of complex genetic pattern from our data. When I speak at meetings with executives of other private and publicly held companies, I am continually amazed at how little effort they are putting into genetics IT and discovery. The reason for this is, that it’s hard, and hard things tend to get done last. Thus, any company that builds a system to solve genetics problems on a genomics scale is worth its’ weight in gold. At the close of year one, DNAPrint is about half way to having our informatics platform for solving these problems completed. We have developed 8 different software components of this platform, and filed patents covering their composition and use. For example, we have filed on a proprietary cladistics-based, geometric modeling scheme for identifying epistatic and dominance components of quantitative genetic variance. To our knowledge, there are no other programs like this anywhere in the world.
We have assembled a world-class laboratory with state-of-the-art equipment. We are sequencing well over 1 Million bases per week and scoring about 2,000 genotypes per day.
We have assembled what may well be the most extensive, detailed and valuable pharmacogenomics specimen databank in the world. We have had the foresight to collect multi-drug consent from our donors, and to log everything in their patient files into our database. No other company does this. Since most of our patients are on multiple medications and since we genotype every person at every pharmaco-relevant marker (unlike our competition), we have the ability to perform multiple and simultaneous pharmacogenomics projects. Please appreciate what this means. Using this type of “master” databank, DNAPrint will be able to outrun its competition in getting pharmacogenomics products discovered and developed to market. For example, when a company decides to do a study on Drug X, they start by collecting specimens, picking markers out of a public database, genotyping and analyzing the results in slow time. Specimen collection, on its’ own, usually takes months. Going on to Drug Y, they start all over again. At DNAPrint, we will use our “master” databank to work 100 times faster. When we decide to look for a solution for problem Y related to use of Drug X, it is simply an informatics problem. The genotypes, patient data, consent – all of it – is in place and ready to be mined the minute we decide we want to spend time on the project. Unlike the competition, we don’t have to start from the beginning collecting specimens, making DNA, building SNP maps, selecting markers, genotyping and analyzing. This imparts a HUGE advantage to DNAPrint.
As you can see, the level at which we are performing here at DNAPrint is about as high as it can be. We are the envy of our larger Nasdaq peers, and this bodes well for the prospects of increased shareholder value in the months and years to come. In fact, our research is already beginning to pay off. It is my personal goal to be able to announce to you, by year’s end, the company’s first product and product license.
You should know that there are only about 40 companies in the entire world with the hardware technology we have and significantly fewer with the analytical/software technology we are developing. You should also know that of all of these genomics-capable companies, we are the only micro-cap. In fact, most pharmaceutical companies would have to spend well over $10 million to set up a division with our capabilities.
This brings up the most important point I will leave you with.
On a budget of about $1 million, a head count of 14 full time employees (10 on and 4 off-site), and a very small market cap of $20 million, we are literally beginning to outrun larger companies in terms of actual results and enabling infrastructure. We are working smarter, building deeper maps, making “master” databanks and building more sophisticated analytical algorithms than companies with budgets 10 times as large as ours. These things lead to products, which will lead to revenues and profits. They can also enhance shareholder value through other mechanisms. We will continue to build and devote ourselves to making DNAPrint a stunning success.
We are the first micro-cap company that I know of, anywhere, to begin to make an impact in the challenging and expensive field of genomics. You should feel proud of the company you have helped build.
Ann
Being a famous writer, she must have many viewers visit her website:
(Highlight DNAP's Louisianna Killer story reviewed)
http://www.patriciacornwell.com/research.html
Ann
As stated in previous post - (sorry):
"Toronto police Detective David Needham of the major sex crimes unit applauded the technology and said it is scheduled to be presented at a conference the force is holding in October.
"If the science is reliable and it can be accepted and established in the courts, it's going to be great," he said."
Ann
Bottom line for (Toronto Police):
"
A recap:
"The company says the so-called DNAWitness test has been used in 80 criminal investigations by law-enforcement organizations worldwide, including the U.S. Federal Bureau of Investigation, the U.S. Army and Scotland Yard.
"This could be helpful in solving crimes, more helpful than human eyewitnesses," said Anthony Frudakis, the company's chief scientific officer.
"Our technology serves as a potential molecular eyewitness. It's objective."
It's also advancing at a dizzying pace. This spring, the company launched a new DNA test that can discern a person's eye colour with 92-per-cent accuracy. Meanwhile, the prospect of learning other physical -- even psychological -- traits could soon follow."
Ann
Tony Frudakis involved in patent for treatment of breast cancer - http://www.pharmcast.com/Patents100/Yr2005/Mar2005/030105/6861506_Breast030105.htm
Ann
DNA Detective Crime Scene Solutions - DNAP:
http://www.genetree.com/product/dna-detective.asp
Ann
Just for review:
(For some unbeknownced reason, websites often cite a month, but, not the year in their id's and postings for articles & info. I'm sure you've noticed this also):
DNAP's association w/Inter-Ad Agency promotion:
http://www.bioportfolio.com/july_05/26_07_2005/DNAPrint_genomics_Launches.html
Ann
Zooluu/Hopeful/oobe
"Taking 3 years on a 80 patient clinical trial with no progress, bla, bla"
You are one and the same aliases...eventually giving your covers away.
Ann
Again, the NIH Grant awarded to DNAP at...connect the dots...
http://www.dnaphenomics.com/pressrelease1-31-05.php
Ann
Not sure on date - but, interesting topics -on DNAP/nanotech, etc.:
http://www.superlynx.com/biotech-investing/dna-print-genomics.html
Ann
Steve:
OT:
"ARE WE ON THE MOON YET?"
How 'bout I let you decide that - lol
Ann
Hello Dolly...er;...Dorsey - lol
Your Biof. IPO info looks very promising. Hope it will materialize for us soon. Certainly something to look forward to.
Take care,
Ann
Eep:
"Thanks for the update"
Your welcome.
Take care,
Ann
Progress on EPO Dimmer:
"DNAPrint Genomics progresses anemia drug development
Published: 15 Mar 2006
DNAPrint Genomics progresses anemia drug development
DNAPrint Genomics' development of commercial grade PT-401, a more powerful form of the anemia drug erythropoietin, is said to be proceeding on schedule with the manufacturing of PT-401 in mammalian cells being shown to be very efficient.
According to the company, erythropoietin (EPO) has a worldwide market exceeding $11 billion and is growing at an average annual rate of 18% for the past five years.
"Based on these results, research is on schedule for our first pharmaceutical product," stated Dr Hector Gomez, chairman and chief medical officer of DNAPrint Genomics. "Tests of our Super EPO dimer in animal models of anemia showed that it was several times more effective and longer acting than the currently available erythropoietin."
In vitro testing in cell cultures revealed significant positive biological activity shown by marked growth stimulation of target mammalian blood cells, either attached to solid surfaces or growing in suspension, according to Dr Gomez.
In addition, in vivo testing in mice demonstrated that even with a single injection, robust stimulation of red blood cell production was produced as assessed by an increase in the number and volume of blood cells. Further analytical testing showed that the dimer exhibits unique biochemical properties that distinguish it from currently marketed red blood cell growth stimulating drugs."
Ann
DNAP Positive:
"Toronto police Detective David Needham of the major sex crimes unit applauded the technology and said it is scheduled to be presented at a conference the force is holding in October.
"If the science is reliable and it can be accepted and established in the courts, it's going to be great," he said.
Ann
DNAP Technology Helps Find Suspects:
http://www.rense.com/general66/suspects.htm
Ann
This introduces Mat Thomas and don't recall this post:
http://sidesearch.lycos.com/?query=dnaprint&first=1&hurl=http%3A%2F%2Fwww%2Edatamonitor%2Eco...
Ann
More DNAP Info on Kits & distributors:
"With most forensics work done by state and federal labs, the kits will enable them to utilize DNAWITNESS technology while running DNA under their own control. We've also signed a number of distributors ' Orchid Biosciences is one of them, as well as ReliaGene and Lynn Peavey' companies which are well known in the forensics and investigative communities as suppliers of crime scene products. Our kit actually will go out through our distributors as well as directly to forensics laboratories. We're in the beta testing stage right now, and we've
selected a number of sites that will be running their analyses with our kits. We also have a database with 2,500 photos that includes eye color, skin shade, hair color and a number of other features ' which brings me to the next point. We recently added another product in DNAPrint's forensics arsenal called RETINOME_, a genetic test for predicting human eye (iris) color from DNA. This is something that's very similar in the
complexities that one would find in human response to a drug ' how it relates to the gene."
Ann
Now 5.0:
http://www.familytreelegends.com/
Ann
This is DNAP's Family Tree Legends 2.0:
http://www.familytreemagazine.com/articles/dec03/legends.html
Ann
Looks like on this one, Trace Genetics temporarily cannot be linked. Stay tuned...
Ann
Gene Tree Business Partners: (Trace Genetics)
http://www.genetree.com/about/genetree-partners.asp
Ann
DNAP partners w/college:
http://www.bizjournals.com/tampabay/stories/2006/02/27/daily64.html?surround=lfn
Ann
MarketGainer DNAP News:
http://www.stockhouse.com/news/news.asp?tick=DNAG&newsid=3510847
Ann
Bend:
I realize this is past news - but, helps to remind us re: many DNAP issues.
Take care,
Ann
Absolutely excellent read re: DNAP:
http://transobj.workopolis.com/servlet/Content/fasttrack/20050625/DNA25?section=Biotech
Ann
Sorry:
Guess we gained other part of Ellipsis acquision
Ann
Anyone decipher this?
http://www.techfinance.ca/m-topnews+news+tnid-863-tnd-20060227.html
Ann
Excerpt from Yang Paper & Reality of Race:
"In both cases – Yang and DNAPrint – “blind” studies of individuals correctly identify majority race with ~ 100% accuracy, as well as identify, in many cases, significant admixture consistent with known population histories and with individual phenotypes. The point being, in the last analysis, is that while a more perfect analysis would be able to detect “true ancestry” and complete “population diversity” (including Australian aboriginals, Papuans, etc.), the more limited set of AIMs and parental populations are currently sufficient to identify major racial and sub-racial populations, and admixture of these, by observing the patterns of genetic components characteristic of each group.
Thus, even if DNAPrint (or Yang et al) would label the different clusters as A,B,C, D and NOT with actual names of population groups, and even if we did not know the exact origin of these genetic components, we could say, for example, that North Europeans are characterized by, typically, a profile of proportions 6A, 2B, 1C, and 1D, while Southern Europeans were 3A, 4B, 2C, and 1D, and Middle Easterners were 0A, 1B, 6C, and 2D, etc.
In any case, in summary:-
Race is real. And South Asians are a different race than Europeans. And the results of the Yang paper are generally consistent with the broad outlines of the racial and sub-racial DNAPrint data."
Ann
Paulness:
OT:
"MONEY4NOTHIN VERY BAD MOVE, GZFX HAS 3.29 BILLION SHARE OUT , IF YOU THINK DNAG WAS SHORTED, WAIT TILL YOU SEE WHAT THE MARKET MAKERS ARE DOING TO THAT STOCK , DEC.13 2005."
Why are you "yelling"? - (Internet definition of all CAPS)
Ann
Wasn't the buy cancelled?
Ann
DNA PhenomicsDNAP Grant:
http://www.dnaphenomics.com/pressrelease1-31-05.php
Ann
Virg:
Do you have Real Player? It seems to require it for play.
Ann
A nice Sun. to you Dorsey,
Ann